Wellington Management Group’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Wellington Management Group's FDMT Position: Q3 2026 in Review
Wellington Management Group increased its 4D Molecular Therapeutics (FDMT) stake by 27% in Q3 2026, buying an estimated $447K and bringing the position to 162,802 shares worth $2.33M. The position accounts for ﹤0.01% of the portfolio, ranked #1585.
Wellington Management Group first reported a position in FDMT in Q4 2020 and has held it in 21 quarters since. The position peaked at $8.67M in Q4 2020. 166 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Wellington Management Group held 162,802 shares of 4D Molecular Therapeutics worth $2.33M as of Q3 2026.
- Wellington Management Group bought 34,338 4D Molecular Therapeutics shares in Q3 2026, an estimated $447K.
- 4D Molecular Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q3 2026, its #1585 holding.
- Wellington Management Group first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 21 quarters since.
- Wellington Management Group's 4D Molecular Therapeutics position peaked at $8.67M in Q4 2020.
- 166 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Wellington Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.